GFP IMAGING FOR IN VIVO HIGH-THROUGHPUT DRUG SCREENING
用于体内高通量药物筛选的 GFP 成像
基本信息
- 批准号:6446853
- 负责人:
- 金额:$ 12万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2001
- 资助国家:美国
- 起止时间:2001-03-08 至 2003-02-28
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
The goal of this application is the development of a clinically-relevant in
vivo high-throughput cancer drug screen. To achieve this goal, we will
further develop mouse models of metastatic cancer with genetically
fluorescent tumors that can be imaged externally in a non-invasive, rapid and
real-time manner suitable for high-throughput screening of anti-tumor,
anti-metastatic and anti-angiogenesis agents. As an important step toward
this goal, we have transduced the green fluorescent protein (GFP) gene, cloned
from the bioluminescent jellyfish Aequorea victoria, into a series of 50 human
and rodent cancer cell lines that stably express GFP in vivo after transplantation
to appropriate rodent models. We have already demonstrated that GFP tumors on
the brain, liver, and bone can be externally, transcutaneously whole-body imaged
quantitatively by fluorescence. In new developments, we have shown that
GFP-expressing tumors and metastasis in the lung can be externally imaged.
The high-throughput models will be developed with the following Specific Aims:
1) Determination of organs involved with metastatic cancer that can be externally
imaged by tumor GFP expression in real-time. External imaging will be
compared with direct imaging of the fluorescent tumors; 2) Determination and
improvement of maximum depth and minimal tumor size for external imaging.
Improvements in resolution will focus on increases in the signal/background
ratio, as outlined below: 1) Ultra-bright GFP-expressing cancer cell clones
will be selected in vitro to enhance size and depth image resolution after
transplantation in vivo; 2) Selective filters, tunable laser and two-photon
imaging to maximize depth and size resolution will be used; 3) Real-time
tumor and metastatic growth and angiogenesis and inhibition by representative
drugs will be imaged and quantified to demonstrate feasibility of use of the
models for a rapid anti-tumor, anti-metastatic and anti-angiogenesis drug
screen. Dose response curves obtained by optical imaging and by standard
tumor measurements will be compared in colon, pancreas, prostate, melanoma and
lung tumor models.
PROPOSED COMMERCIAL APPLICATION:
Externally-imageable, genetically-fluorescent metastatic mouse models of all major cancer
types will be developed for rapid screening for novel effective anti-tumor, anti-metastatic
and anti-angiogenic agents. The current market size for in vivo testing of new cancer drugs
is rapidly expanding as new technologies of genomics, proteomics, and combinatorial
chemical synthesis and high-throughput in vitro screening provide provide numerous new
leads that must be tested and validated in vivo.
本应用程序的目标是开发临床相关的
项目成果
期刊论文数量(10)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Efficacy of camptothecin analog DX-8951f (Exatecan Mesylate) on human pancreatic cancer in an orthotopic metastatic model.
- DOI:
- 发表时间:2003
- 期刊:
- 影响因子:11.2
- 作者:F. Sun;A. Tohgo;M. Bouvet;S. Yagi;Rounak Nassirpour;A. Moossa;R. Hoffman
- 通讯作者:F. Sun;A. Tohgo;M. Bouvet;S. Yagi;Rounak Nassirpour;A. Moossa;R. Hoffman
Determination of clonality of metastasis by cell-specific color-coded fluorescent-protein imaging.
通过细胞特异性颜色编码荧光蛋白成像确定转移克隆性。
- DOI:
- 发表时间:2003
- 期刊:
- 影响因子:0
- 作者:Yamamoto,Norio;Yang,Meng;Jiang,Ping;Xu,Mingxu;Tsuchiya,Hiroyuki;Tomita,Katsuro;Moossa,AR;Hoffman,RobertM
- 通讯作者:Hoffman,RobertM
Viable circulating metastatic cells produced in orthotopic but not ectopic prostate cancer models.
- DOI:
- 发表时间:2003-07
- 期刊:
- 影响因子:11.2
- 作者:A. Glinskii;Brian A. Smith;P. Jiang;Xiaoming Li;Meng Yang;R. Hoffman;G. Glinsky
- 通讯作者:A. Glinskii;Brian A. Smith;P. Jiang;Xiaoming Li;Meng Yang;R. Hoffman;G. Glinsky
Real-time optical imaging of primary tumor growth and multiple metastatic events in a pancreatic cancer orthotopic model.
- DOI:
- 发表时间:2002-03
- 期刊:
- 影响因子:11.2
- 作者:M. Bouvet;Jinwei Wang;S. Nardin;Rounak Nassirpour;Meng Yang;E. Baranov;P. Jiang;A. Moossa;R. Hoffman
- 通讯作者:M. Bouvet;Jinwei Wang;S. Nardin;Rounak Nassirpour;Meng Yang;E. Baranov;P. Jiang;A. Moossa;R. Hoffman
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MENG YANG其他文献
MENG YANG的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MENG YANG', 18)}}的其他基金
Pancreatic-Cancer Imageable Patient-Derived Orthotopic Xenografts (iPDOX)
胰腺癌可成像患者来源的原位异种移植物 (iPDOX)
- 批准号:
8780448 - 财政年份:2014
- 资助金额:
$ 12万 - 项目类别:
Orthotopic models of tumor angiogenesis and blood flow
肿瘤血管生成和血流的原位模型
- 批准号:
7160990 - 财政年份:2003
- 资助金额:
$ 12万 - 项目类别:
Orthotopic models of tumor angiogenesis and blood flow
肿瘤血管生成和血流的原位模型
- 批准号:
7292746 - 财政年份:2003
- 资助金额:
$ 12万 - 项目类别:
Orthotopic models of tumor angiogenesis and blood flow
肿瘤血管生成和血流的原位模型
- 批准号:
6582762 - 财政年份:2003
- 资助金额:
$ 12万 - 项目类别: